A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
A Phase 2, single arm, open label clinical study to evaluate the efficacy, safety,
tolerability and pharmacokinetics of YY-20394 as monotherapy in patients with
relapsed/refractory follicular non-Hodgkin's lymphoma who have failed at least two prior
systemic therapies